SVB Leerink Brokers Boost Earnings Estimates for Applied Molecular Transport Inc. (NASDAQ:AMTI)

Applied Molecular Transport Inc. (NASDAQ:AMTI – Get Rating) – Equities researchers at SVB Leerink lifted their Q1 2023 EPS estimates for Applied Molecular Transport in a report released on Monday, March 13th. SVB Leerink analyst J. Schwartz now anticipates that the company will post earnings of ($0.60) per share for the quarter, up from their prior estimate of ($0.66). SVB Leerink currently has a “Market Perform” rating on the stock. The consensus estimate for Applied Molecular Transport’s current full-year earnings is ($1.65) per share. SVB Leerink also issued estimates for Applied Molecular Transport’s Q3 2023 earnings at ($0.60) EPS, Q4 2023 earnings at ($0.60) EPS, FY2023 earnings at ($1.13) EPS and FY2024 earnings at ($1.21) EPS.

AMTI has been the subject of a number of other reports. Jefferies Financial Group lowered shares of Applied Molecular Transport from a “hold” rating to an “underperform” rating in a research note on Wednesday, February 8th. Chardan Capital reissued a “buy” rating on shares of Applied Molecular Transport in a research note on Monday, March 6th. JMP Securities downgraded Applied Molecular Transport from a “market outperform” rating to a “market perform” rating in a report on Friday, December 23rd. Finally, Bank of America downgraded Applied Molecular Transport from a “buy” rating to an “underperform” rating in a report on Thursday, January 5th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $32.50.

Applied Molecular Transport Trading Up 8.1 %

Shares of AMTI opened at $0.40 on Thursday. The firm has a market capitalization of $15.68 million, a P/E ratio of -0.12 and a beta of 2.08. Applied Molecular Transport has a 12-month low of $0.33 and a 12-month high of $8.02. The firm has a fifty day moving average price of $0.56 and a 200-day moving average price of $0.87.

Institutional Trading of Applied Molecular Transport

Several institutional investors and hedge funds have recently made changes to their positions in the company. EPIQ Capital Group LLC raised its holdings in shares of Applied Molecular Transport by 0.3% in the first quarter. EPIQ Capital Group LLC now owns 9,098,780 shares of the company’s stock valued at $68,423,000 after acquiring an additional 23,292 shares in the last quarter. BlackRock Inc. raised its holdings in Applied Molecular Transport by 5.9% in the first quarter. BlackRock Inc. now owns 2,053,572 shares of the company’s stock worth $15,443,000 after purchasing an additional 114,128 shares in the last quarter. Vanguard Group Inc. raised its holdings in Applied Molecular Transport by 41.4% in the third quarter. Vanguard Group Inc. now owns 1,350,774 shares of the company’s stock worth $1,314,000 after purchasing an additional 395,200 shares in the last quarter. UBS Group AG bought a new position in Applied Molecular Transport in the third quarter worth about $1,257,000. Finally, Founders Fund VI Management LLC raised its holdings in Applied Molecular Transport by 153.1% in the fourth quarter. Founders Fund VI Management LLC now owns 826,607 shares of the company’s stock worth $347,000 after purchasing an additional 500,000 shares in the last quarter. 59.47% of the stock is currently owned by institutional investors.

About Applied Molecular Transport

(Get Rating)

Applied Molecular Transport Inc, a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications.